Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Incyte (INCY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Will Incyte (INCY) Gain on Rising Earnings Estimates?

Incyte: An Undervalued Biotech With Catalysts

Slack

It's impressive what a solid quarter or a positive analyst note will do for a publicly traded company.

2 Stocks That Crushed It on Tuesday

Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q3 2019 Results - Earnings Call Transcript

Incyte (INCY) reports better-than-expected results for the third quarter of 2019, owing to strong Jakafi sales.

Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View

Incyte (INCY) delivered earnings and revenue surprises of 26.15% and 2.34%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) Q3 Earnings and Revenues Top Estimates

Incyte earnings and revenue topped third-quarter views. Early Tuesday, Incyte stock rallied, signaling a move above a long-term technical level.

Incyte Earnings Top, Stock Pops

Amgen

Merck

Pfizer

Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.

Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More

GlaxoSmithKline

Jazz Pharmaceuticals

Vertex Pharmaceuticals

Zoetis

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.

5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3

Incyte has been struggling lately, but the selling pressure may be coming to an end soon.

Incyte Sees Hammer Chart Pattern: Time to Buy?

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2019 results.

Will Strong Jakafi Sales Drive Incyte's (INCY) Q3 Earnings?

The company is a one-trick pony, but should generate profits for the foreseeable future. Can the pipeline finally come through for investors?

Is Incyte a Buy?

Incyte Corp. shares INCY, +1.37% rose 1.2% in premarket trade Wednesday, after the biotech said a late-stage trial of a treatment for patients with steroid-refractory acute graft-versus-host disease, or GVHD, met its main goal of improving overall response rate.

Incyte rerpots positive results in late-stage trial of treatment for GVHD

Bristol-Myers

Drug stocks have moved higher after an upbeat European cancer conference. Play three leading names using these tactical trading ideas.

3 Drug Stocks Poised for Gains After Cancer Conference

Is  (INCY) Outperforming Other Medical Stocks This Year?

Is Incyte (INCY) Stock Outpacing Its Medical Peers This Year?

The Netflixes of tomorrow are here today.

Incyte Corp: Maybe The Next Netflix

Incyte (INCY) outperforms the industry on strong performance of Jakafi and encouraging pipeline progress.

Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance

Incyte (INCY) treats first patient in the TRuE-V clinical program on the cream formulation of ruxolitinib for the treatment of vitiligo.

Incyte Treats First Patient in Phase III Vitiligo Study

The company's flagship drug is finally getting enough traction to drive major margin improvements.

This Could Be a Big Year for Incyte

Biotech company Incyte could parlay its drug, Jakafi, into $300 million in 2025 sales, an analyst said Thursday as he upgraded Incyte stock. Jakafi also is used to treat two forms of cancer.

Why This Biotech Stock Has 'Limited Downside' After 22% Gain This Year

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Why Is Incyte (INCY) Down 4.2% Since Last Earnings Report?

Ionis Pharma

Invesco Dynamic Biotechnology & Genome ETF

Most of the financial markets have trended lower in recent weeks, but biotech seems to have countered the trend.

3 Charts That Suggest Now Is the Time to Buy Into Biotech

Incyte is a biotech company with key drugs in its portfolio in oncology and hematology.

Buy Incyte On Attractive Risk/Reward

The biotech beat Wall Street revenue and earnings estimates in Q2. And it could have more good news on the way.

Here's What You'll Want to Know About Incyte's Impressive Q2 Results

Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q2 2019 Results - Earnings Call Transcript

News for Incyte Stock (INCY)